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Hepatitis C virus (HCV) infection has been associated with autoimmunity and extrahepatic manifestations in adults. Few data
are available on these topics in children. Nonorgan specific auto-antibodies development is part of the natural course of chronic
hepatitis C in children. Smooth muscle autoantibody is the most common autoantibody found, while liver-kidney microsomal
type-1 antibody positivity is the most peculiar autoimmune feature of children with HCV infection. The clinical significance
of non-organ specific autoantibodies in the course of paediatric chronic hepatitis C is still debated. Autoantibody positivity
can be considered neutral for most patients, while it can be associated with negative connotations for others, especially those
positive for liver-kidney microsomal type-1 autoantibody. Subclinical hypothyroidism but not autoimmune thyroiditis has been
demonstrated in HCV infection in children, while only few cases of HCV-associated membranoproliferative glomerulonephritis
have been described. Single reports are available in the literature reporting the anecdotal association between chronic hepatitis
C and other extrahepatic manifestations such as myopathy and opsoclonus-myoclonus syndrome. Despite the low incidence of
extrahepatic manifestations of chronic hepatitis C in children, overall, available data suggest a careful monitoring.
1. Introduction
Since its discovery in 1989 [1], hepatitis C virus (HCV)
has been associated with autoimmunity and extrahepatic
manifestations [2]. Data on these topics in children are
scarce, but the incidence of extrahepatic manifestations is
overall lower in children with chronic hepatitis C when
compared to adults [2–6]. The purpose of the present article
is to summarize the current knowledge on autoimmunity
and extrahepatic manifestations in treatment-naı¨ve children
with chronic HCV infection.
2. Nonorgan Specific Autoantibodies
Nonorgan specific autoantibodies (NOSAs) development
is considered part of the natural course of chronic HCV
infection in children [3–6]. Different mechanisms have
been implicated in the development of NOSAs during
chronic hepatitis C [7]. The high prevalence of NOSAs
in adults is considered the clear evidence of the altered
immune system homeostasis in chronically infected patients.
The characteristic lymphotropism of HCV could be one
of the bases of the increased production of autoantibod-
ies. It has been hypothesized that HCV interacting with
B lymphocytes can lower the B-cell activation threshold
favouring autoantibodies production, and that HCV, such
as other hepatitis viruses, triggers autoimmune response
via a molecular mimicry mechanism. Molecular mimicry
originates when the target of the immune response to a
microorganism shares similarities with a “self” antigen,
and the original antimicrobial immune response becomes
cross-reactive with the “self,” that is, autoimmune. By
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Table 1: Studies investigating the prevalence of nonorgan specific auto-antibodies in children with chronic hepatitis C.
n NOSAs SMA ANA LKM-1 Dilution threshold of positivity Sample/s used
Bortolotti et al. 1996 [3] 40 32.5% 17.5% 7.5% 10% 1 : 20 Single point determination
Gregorio et al. 1998 [4] 51 65% 51% 10% 8% 1 : 10 Sequential serum samples
Muratori et al. 2003 [5] 47 34% 17% 9% 15% 1 : 10 Single point determination
Gehring et al. 2006 [6] 39 8% 5% — 2% 1 : 40 Two serum samples
Note: NOSAs, nonorgan specific autoantibodies; SMA, smooth muscle autoantibody; ANA, antinuclear antibody; LKM-1, liver kidney microsomal type-1
auto-antibody.
a complementary mechanism, HCV can induce cellular
injury determining the release of “self” antigens that are
normally protected from the immune system but when
released are able to elicit an autoimmune response [8, 9].
The prevalence of NOSAs in children with chronic HCV
infection has been investigated in few studies, and wide
ranges of positive results have been found (Table 1) [3–
6]. The heterogeneity of the prevalence estimations among
different studies is due probably to technical differences
in the laboratory methods used and to the fluctuating
behaviour of autoantibodies. For these reasons studies based
on determinations of NOSAs on serial samples [4], using
lower dilution thresholds of positivity [4, 5] and more sen-
sitive laboratory methods [4], had results higher than those
based on single point determinations [3, 5], using higher
thresholds of positivity [3, 6] and less sensitive methods.
Firstly, in 1996 Bortolotti et al. [3] analyzed the preva-
lence of NOSAs in forty Italian children with chronic
HCV infection. About one third of the children studied
had circulating NOSAs smooth muscle autoantibody (SMA)
being the most common autoantibody found. Interestingly,
in this cohort, patients with liver-kidney microsomal type-
1 (LKM-1) autoantibody were more often infected by HCV
genotypes 1 and 2, while no difference was found between
autoantibodies positive and negative cases with respect to
clinical features, γ-globulins levels, and liver histology. Few
years later, in 1998 Gregorio et al. [4] in a cohort of fifty-
one children with chronic infection using a lower dilution
threshold of positivity (1 : 10) and a homemade substrate for
indirect immunofluorescence found an higher prevalence of
autoantibodies positivity (65%). SMA was again the most
common autoantibody detected being present in 51% of the
patients. Twenty-nine percent of the patients enrolled were
positive for antibodies to gastric parietal cells [4]. Muratori et
al. in 2003 [5] found NOSAs in 34% of forty-seven children,
and they did not find any difference in clinical, virological,
and biochemical parameters between NOSAs-positive and -
negative children. Confirming previous findings in adults,
NOSAs negative children in this cohort had significantly
higher HCV viral load than those with NOSAs. As a
possible explanation the authors speculated that the unbal-
anced immune reaction determining autoimmunity creates
a cytokine environment which hampers viral replication [5].
In all the studies examined NOSAs titres were usually lower,
and the antigenic specificity by indirect immunofluorescence
was different than that usually found in children with
autoimmune hepatitis (AIH) [3–5]. Antinuclear antibodies
(ANA) presented with a speckled rather than homogeneous
pattern and SMA reacted only with vessels, sparing glomeru-
lar and tubular structures which are additional targets in
AIH type 1. Not all the children studied presented LKM-1
positivity reacting with the cytochrome P45IID6 (CYP2D6)
that is the common target of LKM-1 autoantibody in type 2
AIH.
In the studies by Gregorio and Muratori [4, 5] children
with chronic hepatitis C were enrolled together with children
with chronic hepatitis B and with other chronic liver diseases
as controls. Overall, NOSAs were more common in children
with chronic hepatitis C than in children with other liver
disorders of similar severity [4, 5], suggesting that the
presence of autoantibodies is not just a consequence of
the chronic liver damage. It is noteworthy that LKM-1
reactivity was not found in any of the controls suggesting
that LKM-1 positivity, even if not the most common, was
the most peculiar autoimmune feature of children with
chronic hepatitis C. Furthermore, LKM-1 prevalence in
HCV-infected children was consistently higher than that
found in studies involving HCV-infected adults [2].
2.1. Clinical Significance of NOSAs. The clinical significance
of NOSAs in the course of chronic hepatitis C is still
debated [7]. The real challenge for clinicians and scientists
is to understand whether and to what extent HCV-induced
autoimmunity contributes to liver damage distinguishing
two theoretically possible populations of children: (1) chil-
dren with HCV infection and histologically silent HCV-
induced autoimmunity and (2) children with HCV infection
and HCV-driven autoimmune liver damage.
As first hypothesis, NOSAs reactivity in children with
hepatitis C could be considered a simple consequence of
hepatocellular damage without pathogenic significance. This
hypothesis is supported by the observation that different
children despite NOSAs presence and persistence have
normal serum aminotransferase level, will not develop other
features of autoimmunity such as increased γ-globulins
levels, and usually have autoantibodies titres lower than that
observed in AIH and with a different pattern as detected
by indirect immunofluorescence [3–5]. On the other hand
autoimmunity could have pathogenetic implications in liver
damage of chronically infected children. Some data sup-
porting this hypothesis are available. In adults some studies
showed that the presence of autoantibodies was associated
with elevated levels of γ-globulins, immunoglobulins, alka-
line phosphatase, and γ-glutamil transpeptidase [10, 11].
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Furthermore, LKM-1 positive HCV-infected children have
been demonstrated to have a more advanced liver disease
when compared with LKM-1 negative peers [12].
Positivity for LKM-1 autoantibody in chronically infect-
ed children appears to have important clinical implication
in view of the significant biochemical deterioration observed
in LKM-1 positive patients who developed marked increases
in aminotransferase activity when treated with interferon-α
[3–5, 12]. This is a hot topic given the recent approval of
the combined treatment with pegylated interferon-α and rib-
avirin by FDA and EMA for children older than three years.
It has been hypothesized that in LKM-1 positive children
interferon-α may amplify the autoimmune response target-
ing CYP2D6 and thereby trigger acute LKM-1 mediated
liver damage. It is important that treatment of LKM-1/HCV
positive patients is decided after thorough investigations to
exclude AIH. The issue of immunosuppressive therapy in
these children is debated as it can improve clinical and
biochemical parameters in selected patients, but it favours
persistent HCV replication.
3. Thyroid
Few data are available regarding natural history of thyroid
dysfunction and thyroid autoimmune disease in children
with chronic HCV infection [4, 6, 13]. Gregorio et al. tested
the presence of antithyroglobulin and antithyroperoxidase
(TPOA) in chronic HCV positive children before and after
treatment with interferon-α with no positive result [4].
Ghering et al. investigating thyroid function and prevalence
of autoimmune phenomena in chronic HCV-infected chil-
dren treated with interferon-α, found a strong correlation
between treatment and emergence of thyroid antibodies [6].
Before treatment all children had normal thyroid function,
one child had an isolate TSH elevation and a further one
had borderline TPOA levels [6]. Indolfi et al. in a case-
control study enrolling a cohort of untreated children with
vertically acquired chronic HCV infection (n = 36), showed
a high prevalence of subclinical hypothyroidism (11%)
and of autoimmune thyroiditis (5.6%) [13]. Subclinical
hypothyroidism was not related to length of infection, or to
different HCV genotypes, but it was related to the presence
of active liver disease. Subclinical hypothyroidism was not
found in children with apparent virus clearance but only in
those with chronic infection and persistent viraemia even
though no correlation was found between development of
subclinical hypothyroidism and levels of viraemia. No child
with subclinical hypothyroidism in this study presented
antithyroid autoantibodies suggesting that the mechanism
of subclinical hypothyroidism in HCV-infected children is
not antibody mediated [13], although autoimmunity cannot
be excluded absolutely as in adults autoimmune thyroiditis
without detectable circulating anti-thyroid antibody titres
has been demonstrated and autoimmunity can be executed
by autoreactive T cells also in the absence of detectable
autoantibodies [14]. The possible role in the genesis of
subclinical hypothyroidism during chronic HCV infection
of the impaired hepatic metabolism of thyroid hormones
[12] and of the thyroid infection by HCV [15] remains
speculative.
4. Kidney
Membranoproliferative glomerulonephritis is the most com-
mon renal disease associated with HCV infection in adults
[2]. To the best of our knowledge only three cases of
HCV-associated membranoproliferative glomerulonephritis
in children have been reported [16–18]. The specific patho-
genesis of the glomerular injury caused by HCV infection is
not known, but it is thought to result from the deposition
of circulating immune complexes of HCV and anti-HCV on
the glomerular capillary in the mesangium [2]. In one of the
three children described, successful antiviral monotherapy
with pegylated interferon-α resulted in HCV RNA clearance
and disappearance of proteinuria [16].
5. Anecdotal Observations
Single reports are available in the literature reporting the
anecdotal association between chronic hepatitis C and extra-
hepatic manifestations. Mohan et al. described a 15-year-old
boy with diabetes, chronic HCV infection, and an inflamma-
tory myopathy presumed to be associated with HCV infec-
tion [19]. The potential association between inflammatory
myopathy and HCV infection has been infrequently reported
in adult patients [20], and an autoimmune mechanism has
been hypothesized. Ertekin and Tan reported a 9-year-old
boy with progressive cerebellar ataxia, action myoclonus,
palpebral flutter, vomiting, headache, and opsoclonus, diag-
nosed with opsoclonus-myoclonus syndrome [21]. This
rare neurologic disorder characterized by multidirectional
chaotic eye movements, myoclonus in the limbs, and ataxia
may be associated with viral infections and for the first time
with hepatitis C [21]. The exact immunopathogenesis of
the disease is undefined [22], but as for other extrahepatic
manifestations of HCV infection, the underlying mechanism
was postulated to be immune system dysregulation.
6. Conclusions
The wide range of extrahepatic manifestations of HCV
in adults suggests that HCV chronic infection should be
considered a systemic disease. An important role in the devel-
opment of extrahepatic manifestations of HCV is thought to
be played by geographic, genetic, or environmental cofactors
as well as by the disease activity [2]. Chronic hepatitis C
is much different in children when compared to adults
with regard to disease activity, response to treatment, and
extrahepatic manifestations. Mixed cryoglobulinaemia, for
example, is the most documented extrahepatic manifestation
of HCV infection in adults and has never been described in
children. Although discussed, the association between mixed
cryoglobulinaemia and severe liver damage has been shown
by different epidemiological studies [2, 23]. The natural
history of chronic hepatitis in children is usually of a mild
disease [24], and the low incidence of severe liver damage
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during childhood could be partly responsible for the absence
of mixed cryoglobulinaemia in children. Despite the low
incidence of extrahepatic manifestations in children, overall,
available data suggest a careful monitoring.
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